Could a simple tablet stop epilepsy after a stroke?
NCT ID NCT07604350
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a tablet called edaravone dexborneol can prevent epilepsy in people who have had a stroke and are at high risk. About 160 adults will receive either the tablet or a placebo for three months, starting within 48 hours of their stroke. Researchers will track seizures and brain activity over two years to see if the treatment helps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Edaravone dexborneol sublingual tablets (edaravone 30 mg plus borneol 6 mg)
What this could lead to
If successful, this could provide a new way to prevent epilepsy in people who have had a stroke, reducing seizures and improving recovery.
What could go wrong
This is an early-stage trial with only 160 participants, so results may not apply to everyone. The treatment also has potential side effects, and it's not yet proven to work.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••